Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Status
- RECRUITING
- Phase
- PHASE3
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Status
- RECRUITING
- Phase
- PHASE3
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
- Status
- RECRUITING
- Phase
- PHASE2
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
- Status
- RECRUITING
- Phase
- PHASE2
Circulating Tumor DNA Response In Urothelial Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of DS5361b in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
- Status
- RECRUITING
- Phase
- PHASE2
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
- Status
- RECRUITING
- Phase
- PHASE3
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
- Status
- RECRUITING
- Phase
- PHASE2
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1